APSNM achieves precise tumor targeting and dual PD-L1 inhibition (intracellularly via downregulation of the p-VEGFR2/p-JAK2/p-STAT3 pathway, intracellularly via p-VEGFR2/p-JAK2/p-STAT3 pathway downregulation, extracellularly via antibody blockade), while simultaneously employing sonodynamic therapy (SDT) to generate reactive oxygen species (ROS) and enhance antitumor immunity, significantly improving treatment outcomes for NSCLC. The gene discussed is CD274; the disease is neoplasm.